any urinary leak) after RP and post IMRT was achieved in 29 (69%) and 27 (64.3%), respectively. After a median follow up of 3.4 years, a PSA recurrence and clinical recurrence were observed in 7 (16.7%) and 4 (9.5%) patients. A 5-year biochemical and clinical recurrencefree survival rate were 70.7% and 84.0%, respectively. 5-year overall free survival was 93.6%. None of patients died for prostate cancer during follow up.
INTRODUCTION AND OBJECTIVES: Recent studies have
shown a possible survival advantage for men with metastatic prostate cancer (MPCa) who undergo local treatment of the primary tumor in addition androgen deprivation therapy (ADT) when compared to ADT alone. We hypothesize that this benefit will depend on the degree of metastatic burden. We assess this by looking at men with varying levels of metastatic disease, and comparing the overall survival (OS) between those who did and did not undergo local therapy in addition to ADT.
METHODS: Patients with MPCa (cNþ or cMþ) who received ADT were identified from the National Cancer Database (NCDB) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) . We categorized men based on the extent of metastatic disease (NIM0, M1a, m1b and M1c). Within each group we modeled the propensity to receive local therapy to the primary. We then compared those undergoing local therapy in addition to ADT to those undergoing ADT alone in a 1:1 propensity matched analysis. Kaplan-Meir curves and Cox proportional Hazards regression were used to compare overall survival (OS) in men receiving local therapy with ADT to ADT alone within each metastatic category.
RESULTS: A total of 17,950 men with MPCa who received ADT were identified. Of these, 1,109 received local treatment and 16,841 did not. After propensity matching we had 1876 patients in the N1M0 group, 76 patients in the M1a group, 244 patients in the M1b group and 12 patients in the M1c group, with an even distribution of men between the two treatment groups in each metastatic category. Survival was not analyzed in the M1c group due to the low number. We found that there was a significant benefit in OS for men underging local therapy in all other sub-groups ( Figure 1 ). Cox regression analysis revealed a benefit from local therapy in all analyzed groups: N1M0: HR¼0.56, 95%CI 0.47-0.67, p<0.001, M1a: HR¼0.3, 95%CI 0.12-0.73, p¼0.008, M1b: HR¼0.54, 95%CI 0.38-0.77, p<0.001.
CONCLUSIONS: CONCLUSIONS: Our study shows a significant benefit in OS for men with MPCa undergoing local therapy in addition to ADT, versus ADT alone in men with N1M0-M1b prostate cancer. These results require further validation, ideally via prospective randomized trials. INTRODUCTION AND OBJECTIVES: Long-term data on the outcomes of aggressive loco-regional surgical resection in prostate cancer (PCa) with nodal involvement are lacking. The present study reports on the impact of adding radical retropubic prostatectomy (RRP) to surgical castration on long-term cancer-specific (CSS) and overall survival (OS) outcomes in men with pathological node-positive (pNþ) PCa.
Source of Funding: None
METHODS: Men with pNþ PCa who underwent pelvic lymphadenectomy and early bilateral orchiectomy (within 90 days of surgery), with (n¼382) or without (n¼79) RRP, were identified . Men who underwent RRP þ orchiectomy and men who underwent orchiectomy alone were matched 1:1 on age, year of surgery, clinical grade, clinical stage, number of positive nodes, and preoperative serum PSA level (after 1987). Kaplan-Meier and Cox regression analyses were used to compare CSS and OS between groups.
RESULTS: The cohort included 158 men (79 in each group) with a mean age of 66 years (SD¼6), of whom 146 (92%) were followed until death. Groups were balanced on all matched parameters. Among men undergoing orchiectomy alone, 76 died, with 60 dying from PCa. Among patients undergoing RRP þ orchiectomy, 70 died, with 28 dying from PCa. On Kaplan-Meier analyses, RRP þ orchiectomy versus orchiectomy alone was associated with significantly improved CSS at 10 years (79% vs. 35%) and 20 years (59% vs. 18%) (log-rank p<0.001). Likewise, RRP þ orchiectomy versus orchiectomy alone was also associated with prolonged OS at 10 years (66% vs 27%) and 20 years (22% vs. 9%)(log-rank p<0.001). In Cox models, RRP þ orchiectomy versus orchiectomy alone was associated with significantly improved CSS (HR¼0.28, 95%CI¼0.17-0.46, p<0.001) and OS (HR¼0.48, 95%CI¼0.34-0.66, p<0.001). Findings were similar in the subset with available pre-operative PSA (CSS: HR¼0.31, 95%CI¼0.16-0.61, p<0.001; OS: HR¼0.45, 95%CI¼0.26-0.77, p¼0.004).
CONCLUSIONS: With nearly the entire cohort having lifelong follow up, this analysis demonstrates that the addition of RRP to surgical castration for pNþ PCa is associated with improved CSS and OS. Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 THE JOURNAL OF UROLOGY â e719
When technically feasible in well-selected patients, aggressive locoregional resection should be considered in node-positive PCa as a part of a multi-modal approach.
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CURRENT MANAGEMENT OF PROSTATE CANCER WITH NODE-POSITIVE DISEASE AFTER RADICAL PROSTATECTOMY AND ITS IMPACT ON OVERALL SURVIVAL Alaa Hamada*, Cleveland, OH; Simon Kim, Cleveland, OH; Hui Zhu, Cleveland, OH; Robert Abouassaly, Cleveland, OH INTRODUCTION AND OBJECTIVES: The optimal treatment approach for lymph node positive prostate cancer (PC) disease (pN1) at the time of radical prostatectomy (RP) and pelvic lymph node dissection (PLND) is uncertain. The aim of our study is to examine current treatment of pN1 and evaluate patient and disease-specific predictors of overall survival (OS).
METHODS: The National Cancer Database (NCDB) was used to identify pN1 patients between 2004-2013. We examined subsequent treatment; radiation (RT) and/or antiandrogen therapy (ADT). Logistic regression was used to identify clinical and oncologic characteristics associated with different treatments. Finally, survival analyses were performed to examine the effect of these treatments on overall survival (OS), adjusted for covariates.
RESULTS: A total of 336,798 PC patients had undergone RP & PLND. pN1 was recorded in 11,742 (3.5%). Approximately half underwent observation (51%), RT alone was used in 7%, RT&ADT were used in 17% and ADT alone was used in 25%. Adjusted multivariate logistic regression indicated that RTþ/-ADT was used for younger and healthier patients who had underwent limited PLND (5 nodes examined), with adverse pathological feature (i.e. intermediate or high grade Gleason score, with locally advanced disease (pT3 or T4) and positive margins. Median follow-up for the entire cohort was 48 months. Unadjusted Kaplan Meier analysis demonstrated significant differences in OS favoring RTþ/-ADT over observation and ADT alone (p<0.0001). Fiveyear OS was 85.7% for observation, 88% for RT& ADT, 89.5% for RT alone and 83% for ADT alone (p<0.0001). Adjusted Cox proportional hazards regression demonstrated an improved OS for RTþADT compared with other groups (Hazard ration 0.75, 95%CI( 0.64 to 0.89), P¼0.001). OS was worse in older men, with worse comorbidity score, higher Gleason score and stage, positive margins and > 2 positive LNs.
CONCLUSIONS: Our study suggests that pN1 disease may be currently undertreated. The combination of RT&ADT appears to offer a survival advantage in select patients. These results highlight the importance of a multimodal approach in the treatment of node-positive prostate cancer. 
Source of Funding: None
INTRODUCTION AND OBJECTIVES:
There is limited evidence supporting the use of local treatment (LT) for prostate cancer (PCa) patients with clinically pelvic lymph node-positive (cN1) disease. Against this backdrop, we sought to examine the efficacy of any form of LTþ/-androgen deprivation therapy (ADT) in treating these individuals.
METHODS: Within the National Cancer Data Base (2004-2012), we identified 2,967 individuals who received LTþ/-ADT vs. ADT alone for cN1 PCa. Only radical prostatectomy (RP) and radiation therapy (RT) were considered as definitive LT. Instrumental variable analyses (IVA) were performed using a two-stage residual inclusion approach to compare overall mortality-free survival between patients who were treated with LTþ/-ADT vs. ADT alone. The same methodology was used to further compare overall mortality-free survival between patients who were treated with RPþ/-ADT vs. RTþ/-ADT.
RESULTS: Overall, 1,987 (67.0%) and 980 (33.0%) patients received LTþ/-ADT and ADT alone, respectively. In the LTþ/-ADT group, 751 (37.8%) and 1,236 (62.2%) patients received RPþ/-ADT and RTþ/-ADT, respectively. In IVA, LTþ/-ADT was associated with a significant overall mortality-free survival benefit (HR¼0.31; 95% CI¼[0.13-0.74]; P¼0.007), when compared to ADT alone (Figure 1) . At 5-year, overall mortality-free survival was 78.8% (95% CI: 74.1%-83.9%) vs. 49.2% (95% CI: 33.9%-71.4%) in the LTþ/-ADT vs. ADT alone groups. When comparing RPþ/-ADT vs. RTþ/-ADT, IVA showed no significant difference in survival between the two treatment modalities (HR¼0.54; 95% CI¼[0.19-1.52]; P¼0.24; Figure 2) . CONCLUSIONS: Our study shows a significant overall mortality-free survival benefit for cN1 PCa patients who were treated with LTþ/-ADT as compared to their counterparts treated with ADT alone. Conversely, no significant survival difference was observed between patients treated with RPþ/-ADT vs. RTþ/-ADT.
